FDA Drug recall D-1058-2017
Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose blister pack per carton, Rx only, Mfd for: Watson…
- FDA Drug
- Class III
- terminated
- Published 2017-08-16
On 2017-08-16 the FDA classified a Class III recall of Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose blister pack per carton, Rx only, Mfd for: Watson… by Teva Pharmaceuticals Usa, citing failed Moisture Limits: out of specification test results for water content obtained during stability testing.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1058-2017 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2017-08-02 |
| Published | 2017-08-16 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Teva Pharmaceuticals Usa |
| Distribution | CT, IL, MI, OH, PA, VA |
Product
Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose blister pack per carton, Rx only, Mfd for: Watson Laboratories, Inc., Corona, CA 92880, Mfd by: Patheon Pharmaceuticals, Inc., Cincinnati, OH 43215, NDC 0591-0844-15
Reason
Failed Moisture Limits: out of specification test results for water content obtained during stability testing.
Identifiers
| code_info | Lot # 3138405A, Exp 8/2017 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1058-2017%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.